Obermatt

Alkem Laboratories

NSI:ALKEM · INE540L01014
PharmaceuticalsLarge

360

47
EV / EBIT36
Price / Owner Earnings43
Owner Earnings Yield56
Dividend Yield65
Price/Sales32
EV / Gross Profit44
Price/Book28
Return on Capital67
Cash Return on Capital73
Return on Equity71
EBIT Margin42
Gross Profitability70
Cash Conversion21
Owner Earnings Margin54
Sales growth53
Profit Growth64
Long-Term EPS Growth45
Reinvestment61
Price momentum59
Debt load61
Refinancing39
Debt Payback100
Liquidity54
Analyst ratings25
Opinion Changes35
Price Target Upside50
Market mood83
Value Creation13/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Alkem Laboratories clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryIndia
IndustryPharmaceuticals
SizeLarge
TypePublic Company
ExchangeNSEI
Founded1973
Employees6,914
ISININE540L01014
Last UpdateApr 2, 2026
Index & Theme
DiabetesNutraceuticalOncologyDermatologyRespiratoryGastroenterologyCardiovascularPain ManagementOsteoporosisNeurologyCentral Nervous SystemHealth CareMedicalPharmaceutical

Description

Alkem Laboratories Limited a pharmaceutical company that engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products. Business Segments The company operates through Prescription Medications, Generic D…

Analysis

Middle-of-the-road

Alkem Laboratories Limited is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is expensive. You pay 28.2× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 11% yearly growth; analysts expect 10%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is sturdy. The company scores 13/20 on our value-creation score: creating some value.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
42
2023202420252026

All-time high

88

Jan 2024

All-time low

22

Jan 2025

Average rank

56

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
32
48
50
59
Price/Earnings
44
58
38
64
Price/Book
28
45
44
54
Dividend Yield
65
56
47
62
Value (overall)
48
61
51
71

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Alkem Laboratories with its peers
Bangkok Lab and Cosmetic
SET:BLC
55
CountryThailand
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Glenmark Pharmaceuticals
NSI:GLENMARK
58
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Cipla
NSI:CIPLA
53
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Ajanta Pharma
NSI:AJANTPHARM
65
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Lupin
NSI:LUPIN
67
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Aurobindo Pharma
NSI:AUROPHARMA
60
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →